ACUR · As filed with the SEC
Acura Pharmaceuticals income statement, by fiscal year
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 | FY2016 Year ended Dec 31, 2016 | FY2015 Year ended Dec 31, 2015 | FY2014 Year ended Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenues: | ||||||||
| License fee revenue | — | — | — | — | 2,500 | 3,500 | 5,250 | 500 |
| Milestone revenue | — | — | — | — | — | 0 | 2,500 | — |
| Collaboration revenue | — | — | — | — | 59 | 392 | 170 | — |
| Royalty revenue | — | — | — | — | 300 | 149 | 5 | 4 |
| Product sales, net | — | — | — | — | 107 | 423 | 662 | 247 |
| Royalties | 132,000 | 109,000 | 372,000 | 410,000 | — | — | — | — |
| Product sales, net | — | — | — | 0 | — | — | — | — |
| Collaboration from related party | 31,000 | 238,000 | 185,000 | 0 | — | — | — | — |
| License fees from related party | 1,400,000 | 3,000,000 | 2,100,000 | 0 | — | — | — | — |
| Product sales | 0 | 223,000 | — | — | — | — | — | — |
| Total revenues | 1,563,000 | 3,570,000 | 2,657,000 | 410,000 | 2,966,000 | 4,464,000 | 8,587,000 | 751,000 |
| Expenses: | ||||||||
| Cost of sales | — | — | — | 0 | 128,000 | 451,000 | 656,000 | 227,000 |
| Inventory provisions (Note 4) | — | — | — | — | 0 | 26 | 330 | 201 |
| Research and development | 1,524,000 | 1,781,000 | 1,505,000 | 1,759,000 | 3,721,000 | 4,028,000 | 2,608,000 | 4,582,000 |
| General and administrative | 1,253,000 | 2,547,000 | 1,877,000 | 2,566,000 | 4,342,000 | 6,516,000 | 8,994,000 | 7,940,000 |
| Total expenses | 2,777,000 | 4,328,000 | 3,382,000 | 4,325,000 | 8,191,000 | 11,021,000 | 12,588,000 | 12,950,000 |
| Operating loss | (1,214,000) | (758,000) | (725,000) | (3,915,000) | (5,225,000) | (6,557,000) | (4,001,000) | (12,199,000) |
| Interest and investment income | — | — | — | — | 4 | 60 | 166 | 198 |
| Gain on sales of marketable securities | — | — | — | — | — | — | — | 4 |
| Loss on debt extinguishment (Note 7) | — | — | (2,600,000) | 296,000 | — | — | — | — |
| Total other income (expense), net | — | — | — | 73,000 | (592,000) | (831,000) | (988,000) | (1,010,000) |
| Loss before income taxes | — | — | — | — | — | — | (4,989) | (13,209) |
| Gain on forgiveness of a loan under CARES Act | 535,000 | — | — | — | — | — | — | — |
| Interest expense to related party | (200,000) | (450,000) | (449,000) | (223,000) | (596,000) | (893,000) | (1,157,000) | (1,212,000) |
| Other income | — | — | — | — | 0 | 2 | 3 | 0 |
| Loss before provision for income taxes | (879,000) | (1,208,000) | (3,774,000) | (3,842,000) | (5,817,000) | (7,388,000) | — | — |
| Provision for income taxes | 0 | 0 | 0 | 0 | (135,000) | 0 | 0 | 0 |
| Net loss | (879,000) | (1,208,000) | (3,774,000) | (3,842,000) | (5,682,000) | (7,388,000) | (4,989,000) | (13,209,000) |
| Unrealized gains (losses) on securities | — | — | — | — | — | — | — | (32) |
| Unrealized gains on marketable securities | — | — | — | — | 0 | 65 | (52) | — |
| Total other comprehensive loss | — | — | — | — | — | — | (52) | (32) |
| Comprehensive loss | — | — | — | — | (5,682) | (7,323) | (5,041) | (13,241) |
| Net income (loss) per share: | ||||||||
| Basic | (0.02) | (0.04) | (0.14) | (0.18) | (0.36) | (0.62) | (0.46) | (0.27) |
| Diluted | (0.02) | (0.04) | (0.14) | (0.18) | (0.36) | (0.62) | (0.46) | (0.27) |
| Weighted average number of shares outstanding: | ||||||||
| Basic | 56,801,000 | 32,320,000 | 26,720,000 | 21,146,000 | 15,903,000 | 11,870,000 | 10,796,000 | 48,893,000 |
| Diluted | 56,801,000 | 32,320,000 | 26,720,000 | 21,146,000 | 15,903,000 | 11,870,000 | 10,796,000 | 48,893,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.